Blueprint Medicines Says Data on BLU-554 Show 16% Objective Response Rate in Hepatocellular Carcinoma

Blueprint Medicines Says Data on BLU-554 Show 16% Objective Response Rate in Hepatocellular Carcinoma

Blueprint Medicines (BPMC) said Monday an ongoing phase 1 clinical trial of BLU-554 demonstrated a 16% objective response rate in patients with FGFR4-driven advanced hepatocellular carcinoma (HCC). In addition, 49% of patients with FGFR4-driven HCC had radiographic tumor reduction. The company said BLU-554 was well-tolerated and most adverse events reported by investigators were grade 1 or 2. Median progression free survival was 3.7 months among patients with FGFR4-driven HCC. The […]

Read More ˃
Overnight Forex Wrap: USD/JPY Tumbles Some 50 pips Since London Open

Overnight Forex Wrap: USD/JPY Tumbles Some 50 pips Since London Open

USD/JPY has tumbled some 50 basis points since the London open, logging lows so far near 108.40. This brings back into scope the 108.33 low seen in the early Asia-Pacific session. Dollar weakness and safe-haven demand for the yen are driving the move. North Korea has escalated tensions by launching a missile over Japan, which comes with shaky political situation in Washington D.C., and as markets try to assess the […]

Read More ˃
Littelfuse Buys IXYS Corporation

Littelfuse Buys IXYS Corporation

Littelfuse said Monday it has agreed to acquire IXYS Corporation (IXYS), a maker of power semiconductors and mixed-signal integrated circuits, for $750 million in cash or stock. Under the agreement, each IXYS shareholder may receive either $23 in cash or 0.1265 Littelfuse shares per share held. IXYS closed at $15.95 on Friday, in a 52-week range between $10.06 and $17.80. Littelfuse said that in total, 50% of IXYS stock will […]

Read More ˃
Foot Locker Shares Drop

Foot Locker Shares Drop

Foot Locker shares dropped to their lowest level since October 2013 on Friday after the retailer of shoes and apparel reported financial results for fiscal Q2 that trailed analysts’ estimates. FL was down 26% recently, in a new 52-week range between $34.55 and $79.43. Adjusted net profit in the quarter ended July 29 was $0.62 per share, down from $0.94 per share in the prior year period and short of […]

Read More ˃
Delphi Automotive Tops Estimates on Q2 EPS and Revenues

Delphi Automotive Tops Estimates on Q2 EPS and Revenues

Delphi Automotive, an automotive technology company, reported Q2 adjusted EPS of $1.71, up from $1.59 in the same period a year ago and topping the estimate of $1.65 from analysts polled by CapIQ. Total revenues of $4.32 billion were up from $4.21 billion in the same period a year ago and exceeded the Street projection of $4.20 billion. The company guided Q3 adjusted EPS in the range of $1.52 to […]

Read More ˃